Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma

NCT07281664 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma
Transarterial Chemoembolization

Interventions

PROCEDURE: Transarterial chemoembolization (TACE)
DRUG: bevacizumab and atezolizumab

Sponsor

Third Affiliated Hospital, Sun Yat-Sen University